News FDA turns down Satsuma’s nasal migraine treatment Manufacturing problems have scuppered Satsuma Pharmaceuticals’ chances of a timely FDA approval for its intranasal migraine therapy STS101.
News Satsuma pulped as acute migraine drug flunks phase 3 trial Shares in California biotech Satsuma Pharma have lost three quarters of their value after lead drug STS01 failed to show any improvement over placebo in an acute migraine study.
